Health Care Equities Analysis -- Research on Raptor Pharma, Intercept Pharma, KYTHERA Biopharma, and Synergy Pharma

LONDON, March 25, 2014 /PRNewswire/ --

On Monday, March 24, 2014, the NASDAQ Composite finished at 4,226.39, down 1.18%, the Dow Jones Industrial Average fell 0.16% to 16,276.69, and the S&P 500 closed at 1,857.44, down 0.49%. The losses were broad based with eight out of ten sectors ending the session in negative. The S&P 500 Health Care Sector Index finished the day at 666.18, down 1.41%, and the same has declined 2.67% in the last one month. Investor-Edge has initiated coverage on the following equities: Raptor Pharmaceutical Corp. (NASDAQ: RPTP), Intercept Pharmaceuticals Inc. (NASDAQ: ICPT), KYTHERA Biopharmaceuticals Inc. (NASDAQ: KYTH) and Synergy Pharmaceuticals Inc. (NASDAQ: SGYP). Free technical research on RPTP, ICPT, KYTH and SGYP can be downloaded upon signing up at:

http://www.investor-edge.com/479-register


Shares in Raptor Pharmaceutical Corp. closed at $10.17 on Monday, which is 4.60% lower than the previous day's closing price of $10.66. A total of 1.72 million shares were traded as compared with three months average volume of 1.31 million. The company's shares oscillated between $10.04 and $10.94 during the trading session. Shares in Raptor Pharmaceutical Corp. have declined 6.87% in the previous three trading sessions, 38.99% in the last one month and 21.89% on YTD basis. The company stock is trading below its 50-day and 200-day moving averages. Raptor Pharmaceutical Corp.'s 50-day moving average of $15.08 is above its 200-day moving average of $13.03. Furthermore, the stock is trading at a Relative Strength Index (RSI) of 24.04. Sign up today to read free research on RPTP at:

http://www.investor-edge.com/479-RPTP-24Mar2014.pdf


Intercept Pharmaceuticals Inc.'s stock witnessed trading of 0.64 million shares on Monday, which is below the three months average volume of 0.90 million shares. The stock ended the day at $366.61, down 6.22%, after trading between $346.37 and $404.45. Intercept Pharmaceuticals Inc.'s shares have declined 16.48% in the previous three trading sessions, 1.74% in the last one month, while the same has surged 436.92% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. Intercept Pharmaceuticals Inc.'s 50-day moving average of $364.37 is above its 200-day moving average of $130.21. Additionally, shares of the company are trading at an RSI of 48.34. Sign up today to read free research on ICPT at:

http://www.investor-edge.com/479-ICPT-24Mar2014.pdf


On Monday, shares in KYTHERA Biopharmaceuticals Inc. advanced 3.15% finishing the session at $42.55. The stock recorded a trading volume of 0.31 million shares which is above the three months average volume of 0.28 million. The company's shares fluctuated between $40.20 and $43.06 during the session. Shares in KYTHERA Biopharmaceuticals Inc. have declined 5.32% in the previous three trading sessions, 23.19% in the last one month, while the stock has gained 13.92% on YTD basis. The stock is trading above its 200-day moving average. KYTHERA Biopharmaceuticals Inc.'s 50-day moving average of $46.21 is above its 200-day moving average of $37.44. Moreover, shares of the company are trading at an RSI of 35.74. Sign up today to read free research on KYTH at:

http://www.investor-edge.com/479-KYTH-24Mar2014.pdf


Synergy Pharmaceuticals Inc.'s stock recorded a trading volume of 2.32 million shares, as compared with a three months average volume of 1.04 million shares. The stock ended Monday's session at $5.99, down 1.48%, after vacillating between $5.82 and $6.15. Synergy Pharmaceuticals Inc.'s shares have fallen by 0.99% in the previous three trading sessions, while the same has gained 1.18% in the last one month and 7.92% on YTD basis. The company stocks is trading above its 50-day and 200-day moving averages. Synergy Pharmaceuticals Inc.'s 50-day moving average of $5.65 is above its 200-day moving average of $4.75. Furthermore, the stock is trading at an RSI of 55.51. Sign up today to read free research on SGYP at:

http://www.investor-edge.com/479-SGYP-24Mar2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://Investor-Edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED